Eli Lilly and Company: Stomach Neoplasms trials
The registry lists 17 Stomach Neoplasms studies with Eli Lilly and Company as lead sponsor. 3 are open to participants now and 10 have results posted.
Phase 1 6Phase 2 8Phase 3 2No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of LY4336619 in Adult Participants With Advanced Solid TumorsNot yet recruitingNCT07928258Phase 1
- A Study of LY4337713 in Participants With FAP-Positive Solid TumorsRecruitingNCT07213791Phase 1
- A Study of LY4257496 in Participants With Cancer (OMNIRAY)RecruitingNCT07114601Phase 1
- A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric CancerCompletedNCT02514551Phase 2Results posted
- A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) CancerCompletedNCT02443883Phase 2Results posted
- A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach CancerCompletedNCT02359058Phase 1Results posted
- A Study of Ramucirumab in Treating Japanese Participants With Metastatic Gastric or Gastroesophageal Junction CancerCompletedNCT01983878Phase 2Results posted
- A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal CancerCompletedNCT01246960Phase 2Results posted
- A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric AdenocarcinomaCompletedNCT01170663Phase 3Results posted
- A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and NeckCompletedNCT01059643Phase 2Results posted
- Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and AdenocarcinomaCompletedNCT00917384Phase 3Results posted
- Pemetrexed Plus Cisplatin as First-Line Treatment in Stage IV or Recurrence of Gastric CancerCompletedNCT00415168Phase 2Results posted
- Study of Pemetrexed Plus Cisplatin in Advanced Gastric CancerCompletedNCT00320515Phase 1/2Results posted
- A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic MalignanciesCompletedNCT02572687Phase 1
- Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in FranceApproved for marketingNCT02307812
- International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric CancerApproved for marketingNCT02065765
- A Study of LY2875358 in Participants With MET Positive, Advanced Gastric CancerCompletedNCT01874938Phase 2